Q-Sub in for Peripheral Nerve Protector
4D Medicine Submits Q-Sub for Peripheral Nerve Protector 4D Medicine has submitted a Q-Submission (Q-Sub) to the U.S. Food and Drug Administration (FDA) for its Peripheral Nerve Protector, in preparation for a planned 510(k) submission later this year. This important step enables early engagement with the FDA to align on regulatory strategy, supporting efficient progression […]
4D Medicine Completes Cadaveric Simulation Testing of Nerve Protector
4D Medicine has successfully completed cadaveric simulation testing of its Peripheral Nerve Protector in collaboration with leading peripheral nerve surgeons. The study provided an important opportunity to evaluate the device in a clinically relevant setting, with surgeons offering expert feedback on performance and usability. The testing delivered highly positive results, demonstrating the product’s effectiveness while […]
Multi-property Material Patent Granted
Second patent granted in the US for 4D Medicine Ltd. We are pleased to share the news of our second patent being granted in the US. The patent, entitled Tunable Materials, with the number US12275186B2, covers the various combinations of material properties that can be achieved in a one-piece implantable medical device using multi-photo-initiated compositions […]
4D Biomaterials Ltd Gains ISO 13485 Certification
We are proud to announce that our wholly-owned subsidiary, 4D Biomaterials Ltd, is now certified to ISO 13485 – the globally recognised standard for medical device quality management systems. This marks a major step in our commercialisation strategy and it validates the growing maturity of our manufacturing operation as we move towards market entry. CEO […]
[PRESS RELEASE] 4D Medicine Raises £3.4m for Unique Biomaterial Platform
Company completes investment deal, led by Oshen Holdings 4D Medicine – a UK company whose innovative biomaterial has potential to be used for a wide range of 3D printed implants and surgical devices – has raised £3.4m ($4.4m) in a Series A investment. The funding round was led by Oshen Holdings and backed by DSW […]
Piers Morgan Joins 4D
Piers Morgan appointed as Chief Financial Officer 4D Medicine have recently welcomed Piers Morgan as Chief Financial Officer. Piers has over 20 years of Board level experience in drug discovery and clinical development in biotech, covering both small molecules and gene therapies. In total, Piers has led financings amounting to almost $800m as principal, and […]
4D Biomaterials Finalist For UKBAA Awards
4D Biomaterials are finalists in the “Deep tech investment of the year” category at the UK Business Angels Association awards! It was a pleasure to have been invited to the London Science Museum to attend the UKBAA Awards night. The night celebrated achievements of high growth and success in the angel and early-stage investment market, […]
Tom Buckland Joins 4D
Tom Buckland appointed as Chairman of the 4D Medicine Group Board We are delighted to welcome Dr Tom Buckland to the 4D team. With a wealth of knowledge in the medical technology sector and experience in fundraising, developing and commercialising technologies, Tom will play a key role in guiding the 4D Board, as it oversees […]
Key Leadership Appointment at 4D Medicine
Dr Andrew Naylor promoted to Chief Operating Officer Having led the R+D function at 4D Medicine since joining the management team in September 2020, Dr Andrew Naylor has been promoted to the new role of Chief Operating Officer for the 4D Group. With this exciting new challenge, Andy will build on his role as operational […]
4D expands operational team at MediCity
We are delighted to announce that the 4D operational team is growing, with five new recruits coming on board in recent months. We would like to give a warm welcome to our new Quality Manager, Karl Houghton, who will be instrumental in developing and maintaining our Quality Management System in line with ISO 13485. His […]